IMGO - IMGO STOCK NEWS

Imago BioSciences (IMGO) has initiated a Phase 2 study for bomedemstat, an oral LSD1 inhibitor, in combination with ruxolitinib to treat myelofibrosis (MF). This investigator-sponsored trial, conducted at the University of Hong Kong, will enroll around 20 participants with varying responses to JAK inhibitors. The study aims to evaluate the safety and efficacy of this combination therapy over 28-day treatment cycles. Bomedemstat is already showing promise in ongoing studies, demonstrating significant symptom improvement in patients with MF and essential thrombocythemia.

Imago BioSciences announced promising data for its Phase 2 study of bomedemstat in patients with essential thrombocythemia (ET). As of October 18, 2022, 100% of 62 patients treated for 24 weeks achieved normal platelet counts. Additionally, 89% of 28 patients treated for 48 weeks maintained this response. The trial reported a 67% decrease in mutant allele frequencies among patients. Notably, the company has aligned with the FDA on the strategy for the upcoming pivotal ET trial.

Imago BioSciences (Nasdaq: IMGO) announced promising results from its Phase 2 trial of bomedemstat for advanced myelofibrosis (MF). As of October 18, 2022, 66% of patients exhibited spleen volume reduction, and 65% showed improved symptom scores after 24 weeks. Remarkably, no patients progressed to acute myeloid leukemia during treatment. The trial is fully enrolled, and an additional study combining bomedemstat with ruxolitinib is in progress. The treatment is reported to be generally safe and well-tolerated, with no new mutations noted.

Merck (NYSE: MRK) has initiated a cash tender offer for all outstanding shares of Imago BioSciences (NASDAQ: IMGO) at $36 per share. This follows a definitive agreement announced on November 21, 2022, to acquire Imago. The tender offer is set to expire on January 10, 2023. Upon successful completion, Imago will merge into a Merck subsidiary and become a wholly-owned entity. The tender offer is subject to conditions, including the tender of a majority of Imago's shares and necessary regulatory approvals. Closing is expected in Q1 2023.

Imago BioSciences (Nasdaq: IMGO) announced the initiation of a Phase 1 study for bomedemstat, an investigational LSD1 inhibitor, in combination with venetoclax for treating relapsed or refractory acute myeloid leukemia (AML). The trial, led by the University of Miami, aims to enroll 18 adult participants who have failed previous therapies. This milestone follows positive outcomes in ongoing Phase 2 studies for myelofibrosis and essential thrombocythemia, where bomedemstat was well-tolerated and improved symptoms. Further details are available at clinicaltrials.gov.

Imago BioSciences (IMGO) reported Q3 2022 financial results, revealing a net loss of $16.8 million, up from $11.7 million YoY. Cash reserves decreased to $178.4 million from $217.4 million in December 2021, yet the company believes its runway extends into 2025. Significant progress was made in clinical trials for Bomedemstat, with completion of enrollment in Phase 2 ET trials and ongoing preparations for Phase 3 ET and Phase 2 PV trials. Positive data for Bomedemstat in ET and MF is expected at the ASH Annual Meeting in December 2022.

Imago BioSciences, a clinical-stage biopharmaceutical company focused on myeloproliferative neoplasms, announced CEO Hugh Young Rienhoff, Jr. will present at two upcoming investor conferences:

• H.C. Wainwright 3rd Annual Precision Oncology Conference: November 14 at 12:30 pm ET
• Stifel Healthcare Conference: November 16 at 8:00 am ET

Live webcasts will be accessible on the company's website, with replays available for 90 days. Imago is developing Bomedemstat, a drug for treating blood cancers, currently in Phase 2 trials.

Imago BioSciences (Nasdaq: IMGO) announced the acceptance of two abstracts for oral presentations at the 64th American Society of Hematology (ASH) Annual Meeting, scheduled for December 10-13, 2022. The presentations will feature the LSD1 inhibitor Bomedemstat (IMG-7289), focusing on its Phase 2 studies for treating essential thrombocythemia and advanced myelofibrosis. Bomedemstat has received Orphan Drug and Fast Track designations from the FDA and EMA, underscoring its potential significance in myeloproliferative neoplasms.

Imago BioSciences (IMGO), a clinical-stage biopharmaceutical company, announced that CEO Hugh Young Rienhoff, Jr., MD, will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. Dr. Rienhoff's pre-recorded presentation will be available for on-demand replay starting at 7:00 AM ET on September 12. The webcast can be accessed via the Investor Relations section of the company’s website, with replay available for 90 days. Imago focuses on developing therapies for myeloproliferative neoplasms and has lead candidate Bomedemstat in Phase 2 trials.